Gerlach Aaron C, Antonio Brett M
a Icagen, Inc ; Durham , NC USA.
Channels (Austin). 2015;9(6):376-9. doi: 10.1080/19336950.2015.1081725. Epub 2015 Nov 10.
A prerequisite for a successful target-based drug discovery program is a robust data set that increases confidence in the validation of the molecular target and the therapeutic approach. Given the significant time and resource investment required to carry a drug to market, early selection of targets that can be modulated safely and effectively forms the basis for a strong portfolio and pipeline. In this article we present some of the more useful scientific approaches that can be applied toward the validation of ion channel targets, a molecular family with a history of clinical success in therapeutic areas such as cardiovascular, respiratory, pain and neuroscience.